ISBN: 9783319969886 - rare kidney tumors: comprehensive multidisciplinary management and emerging therapies (2 Ergebnisse)

Optimieren Sie Ihre Suche

  • Bücher (2)

bis

Benutzerdefinierte Preisspanne (EUR)

bis

  • Sprache: Englisch

    Verlag: Cham, Springer., 2019

    3319969889 / 9783319969886

    • Hardcover

    Anbieter: Universitätsbuchhandlung Herta Hold GmbH, Berlin, DeutschlandUniversitätsbuchhandlung Herta Hold GmbH

    Verkäufer/-in mit 3 Sternen
    Verkäufer/-in kontaktieren

    Verbandsmitglied: VDAGIAQILAB

    Zustand: Gebraucht

    EUR 17,00

    EUR 30,00 Versand 
    Versand von Deutschland nach USA

    Anzahl: 2 verfügbar

    IX, 128 p. Hardcover. Versand aus Deutschland / We dispatch from Germany via Air Mail. Einband bestoßen, daher Mängelexemplar gestempelt, sonst sehr guter Zustand. Imperfect copy due to slightly bumped cover, apart from this in very good condition. Stamped. Sprache: Englisch.

  • Sprache: Englisch

    Verlag: Springer, 2018

    3319969889 / 9783319969886

    • Hardcover

    Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 64,87

    EUR 35,00 Versand 
    Versand von Deutschland nach USA

    Anzahl: 1 verfügbar

    Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book provides clinicians with clear guidance on treatment decision-making in patients with rare kidney cancers. After a brief review on epidemiology, pathology, and biology, each chapter focuses on the multidisciplinary management of a particular tumor subtype using the full range of available cancer therapy modalities, including surgery, radiotherapy, chemotherapy, targeted therapies, and immunotherapy. Emerging therapies and future directions in the management of each cancer subtype are also discussed. The chapters are all written by multidisciplinary teams of international experts comprising at least a urologist, a medical oncologist, and a pathologist. Rare kidney cancers represent 15% of renal cell carcinomas. In comparison with clear cell renal cell carcinomas, little is known about the biology of such cancers, and few trials have reported on the efficacy of targeted therapies in the metastatic setting. Optimal management thus poses significant challenges and often requires a multidisciplinary team. This book will be an ideal reference guide for all clinicians involved in the care of patients with these orphan tumors.…